Mersana Therapeutics, INC

Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc. for $25.00 per share in upfront cash plus contingent value rights worth up to an additional $30.25 per share.

Mersana Therapeutics will be acquired by Day One Biopharmaceuticals for an upfront cash payment of $25.00 per share plus potential contingent value rights of up to $30.25 per share, totaling up to $285 million.

Day One Biopharmaceuticals will acquire Mersana Therapeutics for an upfront cash payment of $25.00 per share, with potential additional payments of up to $30.25 per share through contingent value rights.

Mersana Therapeutics received a notice from Nasdaq for failing to meet the minimum $50 million Market Value of Listed Securities requirement.

Mersana Therapeutics reported Q2 2025 financial results and provided updates on its clinical-stage antibody-drug conjugate programs, Emi-Le and XMT-2056.

Mersana Therapeutics, Inc. will implement a 1-for-25 reverse stock split effective July 25, 2025, to meet Nasdaq's minimum bid price requirement for continued listing.

Mersana Therapeutics announces a definitive merger agreement with Day One Biopharmaceuticals, alongside continued operating losses and a strategic restructuring plan.

Mersana Therapeutics reported increased net losses and substantial doubt about its ability to continue as a going concern, despite positive early clinical data for its lead ADC candidate, Emi-Le.

Mersana Therapeutics announces Q1 2025 financial results and a strategic restructuring plan to extend cash runway into mid-2026.

Mersana Therapeutics' Q3 2024 report shows a significant decrease in net loss compared to the same period last year, driven by reduced operating expenses.

Mersana Therapeutics, a clinical-stage biopharmaceutical company, announced its second quarter 2024 financial results and updates on its antibody-drug conjugate (ADC) development programs.

Mersana Therapeutics reported a net loss of $19.3 million for the first quarter of 2024, while advancing its clinical programs for XMT-1660 and XMT-2056.

Mersana Therapeutics details its 2024 financial results and provides updates on its clinical programs, including Emi-Le and XMT-2056.

Mersana Therapeutics appoints a new SVP, Strategic Product Planning & Program Leadership, and details compensation policies for non-employee directors.

Andrew Hack, a director of Mersana Therapeutics, Inc., disposed of all his direct and indirect common stock and stock options following the company's merger with Day One Biopharmaceuticals, Inc.

Mersana Therapeutics director Kristen Hege reported the disposition of all her common stock and stock options following the company's merger with Day One Biopharmaceuticals.

Mersana Therapeutics Director Allene Diaz disposed of all common stock and options following the company's merger with Day One Biopharmaceuticals.

Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc., with Director Willard H. Dere reporting the disposition of his common stock and stock options as part of the merger.

Mersana Therapeutics, Inc. completed its merger with Day One Biopharmaceuticals, Inc., converting executive Alejandra Carvajal's equity holdings into cash and contingent value rights.

Mohan Bala, SVP of Mersana Therapeutics, reported the disposition of all his common stock, stock options, and restricted stock units following the company's merger with Day One Biopharmaceuticals.

Mersana Therapeutics will hold its annual stockholder meeting on June 12, 2025, to vote on director elections, executive compensation, auditor ratification, and a proposed reverse stock split.

Mersana Therapeutics is asking stockholders to approve a reverse stock split to boost its stock price and maintain its Nasdaq listing.

Mersana Therapeutics announces its annual stockholder meeting to be held virtually on June 11, 2024, with voting open until June 10, 2024.

Mersana Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 11, 2024, covering director elections, executive compensation, and auditor ratification.

Bain Capital Life Sciences reports 0% ownership in Mersana Therapeutics following its acquisition by Day One Biopharmaceuticals for $25.00 cash plus CVR per share.

Bain Capital Life Sciences entities have agreed to tender their 6.9% stake in Mersana Therapeutics as part of a tender offer by Day One Biopharmaceuticals.

683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman have filed a Schedule 13G amendment indicating they no longer beneficially own any shares of Mersana Therapeutics, Inc. common stock following a merger.

683 Capital Management, LLC and its affiliates disclosed a 7.03% beneficial ownership stake in Mersana Therapeutics, Inc. as of December 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, disclosing a 4.20% beneficial ownership in Mersana Therapeutics Inc. common stock, indicating a reduction below the 5% threshold.

Nextech Crossover I GP S.a. r.l. and related entities have filed an amended Schedule 13G, reporting a complete divestment of their beneficial ownership in Mersana Therapeutics, Inc. common stock.

683 Capital Management, LLC and its affiliates have reported a 5.47% beneficial ownership stake in Mersana Therapeutics, Inc. common stock.

Schonfeld Strategic Advisors LLC has reported a 5.48% beneficial ownership stake in Mersana Therapeutics, Inc., holding 273,579 shares of common stock.